According to Company, it has developed a high throughput, high sensitivity methodology for characterizing genetic variants implicated in malignant neoplasia. Through the development and use of high throughput genome scanning with proprietary endonucleases, forward and reverse Sanger sequencing, and unparalleled variant annotation, Transgenomic can reliably detect pathogenic genetic mutations.
In making the announcement, Transgenomic's President and Chief Executive Officer, Craig Tuttle, stated, "The contract with OSI Pharmaceuticals enables Transgenomic to utilize its highly developed expertise in genetic variant detection to assist OSI Pharmaceuticals, Inc. in its development efforts. This contract follows genetic analysis work done with other pharmaceutical companies. It is one of the ways Transgenomic can contribute to the development of therapeutics that benefits patients."